Formulary decision guides

If you want to update your knowledge on specific drugs, or need to collate information to support your formulary decisions, read our Guidelines in Practice formulary decision guides. Items may contain pharmaceutical promotional information.

FINAL Feraccru FDG images

FERACCRU® (ferric maltol) 30 mg hard capsules

Commissioned by Norgine Pharmaceuticals Limited

Information intended for UK healthcare professionals only. This formulary decision guide is promotional and was developed from content provided by Norgine Pharmaceuticals Limited in a format developed by Guidelines in Practice (contains promotional information).
View FERACCRU®  (ferric maltol) prescribing information and adverse event reporting information here
UK-HAE-FER-2100127
Date of preparation: December 2021

Jardiance HF FDG_index image

Jardiance® (empagliflozin) film-coated tablets for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF)

Promotional material from the Boehringer Ingelheim and Lilly Alliance

This formulary decision guide was commissioned by the Boehringer Ingelheim and Lilly Alliance. 
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105819 October 2021

Klisyri (tirbanibulin) FDG - digital

Klisyri▼ (tirbanibulin) 10 mg/g ointment

Commissioned by Almirall Ltd

This formulary decision guide was developed from content provided by Almirall Ltd in a format developed by Guidelines in Practice. It was commissioned by Almirall Ltd, who carried out full medical approval to ensure compliance with regulations.
View prescribing and adverse event reporting information
UK-KLI-2100017 | Date of preparation: October 2021

20210927 Sixmo FDG new image

Sixmo®▼ (buprenorphine) 74.2 mg implant

Commissioned by Accord UK Ltd

Information intended for UK healthcare professionals only. This formulary decision guide was developed from content provided by Accord Healthcare Limited in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting information.
UK-03417
Date of preparation: October 2021

Ipinnia XL (ropinirole hydrochloride) FDG

Ipinnia® XL (ropinirole hydrochloride) prolonged-release tablets

Commissioned by Ethypharm UK Ltd

This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-IPN-13  Date of preparation: September 2021

Xaggitin XL (methylphenidate hydrochloride) FDG

Xaggitin XL (methylphenidate hydrochloride) prolonged-release tablets

Commissioned by Ethypharm UK Ltd

This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-XAG-20  Date of preparation: July 2021

Steglatro FDG inxed image

Steglatro®▼ (Ertugliflozin)

Commissioned by MSD UK Ltd

This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
Prescribing Information (Great Britain) & (Northern Ireland), and Adverse Event Reporting Information
GB-STE-00433 | June 2021

FINAL index image

Trurapi▼ (insulin aspart 100 units/ml)

Commissioned by Sanofi Ltd

This formulary decision guide was developed from content provided by Sanofi Ltd in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
MAT-GB-2101070(v2.0) | Date of preparation: July 2021